Delivery Order SPE2DB24D2205-SPE2DB25FDTLB

Award Date 10/30/24
Potential Completion Date 10/31/24
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $7,607.77, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Candesartan Cilexetil 32 mg tablets, a cardiovascular medication, with an ultimate completion date of November 26, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support...
This federal contract award, valued at $7,632.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Candesartan Cilexetil 16 mg tablets, a cardiovascular medication. The contract has an ultimate completion date of October 23, 2024 and was awarded on October 22, 2024. It is a firm fixed-price contract, with no set-aside designation....
This federal contract award, valued at $4,504.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 32 mg tablets, a cardiovascular medication, with an ultimate completion date of December 4, 2024. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support...
This federal contract award, valued at $27,900.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 32 mg tablets, a cardiovascular medication, and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $7,570.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 16 mg tablets, a cardiovascular medication. This is a firm fixed-price delivery order contract that will run through January 14, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,839.45, is a delivery order for the supply of Candesartan Cilexetil 8 mg tablets. It is a firm fixed-price contract with an ultimate completion date of April 24, 2025. The contract is not designated as a set-aside and was awarded as part of Amerisourcebergen's larger Indefinite Delivery...
This federal contract award, valued at $12,009.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Candesartan Cilexetil 32 mg tablets. The contract is a Firm Fixed Price Delivery Order with a performance period through January 30, 2025. AmerisourceBergen holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as the primary vehicle for...
This federal contract award, valued at $23,571.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 32 mg tablets in 90-count packages. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,932.77, is for the delivery of Candesartan 8mg tablets, a cardiovascular medication. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with a total ceiling value of $999,999,999, which serves as a primary vehicle for providing a comprehensive range...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,247.80, is for the delivery of Candesartan Cilexetil 8mg tablets. It is a firm fixed-price delivery order contract with a completion date of September 17, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FDTLB
    Delivery Order

This federal contract award, valued at $9,959.49, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Candesartan Cilexetil 32 mg tablets, a cardiovascular medication, with a performance period through October 31, 2024. This contract award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, for similar medical products and prescription drugs.

Generated 5/20/25, 1:57 PM